Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB(1)) Receptor Antagonist

BACKGROUND: Cannabinoid 1 (CB(1)) receptor antagonists exhibit pharmacological properties favorable for the treatment of obesity and other related metabolic disorders. CE-178253 (1-[7-(2-Chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-[1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadcock, John R, Carpino, Philip A, Iredale, Philip A, Dow, Robert L, Gautreau, Denise, Thiede, Lucinda, Kelly-Sullivan, Dawn, Lizano, Jeffrey S, Liu, Xingrong, Van Deusen, Jeffrey, Ward, Karen M, O'Connor, Rebecca E, Black, Shawn C, Griffith, David A, Scott, Dennis O
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933614/
https://www.ncbi.nlm.nih.gov/pubmed/20712891
http://dx.doi.org/10.1186/1471-2210-10-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933614/
https://www.ncbi.nlm.nih.gov/pubmed/20712891
http://dx.doi.org/10.1186/1471-2210-10-9

Ejemplares similares